← Eichor
Study identifier: NCT05216328 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Prevention of Opioid-induced Constipation in Patients With Advanced Cancer

Condition: Constipation, Opioid-Induced  ·  Sponsor: Amsterdam UMC, location VUmc

PhasePhase 4
Planned participants330
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

More than 70% of patients with cancer in the palliative phase have pain that often requires treatment with opioids (morphine-like agents). Constipation occurs in 59% of patients treated with opioids. Opioid-induced constipation (OIC) has consequences that range from daily discomfort with social insecurity and disability to intestinal obstruction. It leads to limitations in self-management, a reduced quality of life and a risk of the need for more care. In the guideline "Diagnosis and treatment of pain in patients with cancer" it is recommended to start preventively with an osmotic laxative such as macrogol/electrolytes or magnesium hydroxide when starting opioids. Macrogol/electrolytes has been proven to be effective for OIC, but is sometimes perceived by patients as unpleasant due to its taste. Magnesium hydroxide, which is less commonly prescribed for OIC, has a neutral taste. Although it is mentioned in the guideline, it is not studied for the treatment of OIC and also not officially registered for this. To support the advice of the guideline and to prove that a choice is possible, it is important to investigate whether there are differences in effectiveness and/or side effects between macrogol/electrolytes and magnesium hydroxide in the prevention of OIC. The aim of this study is to compare macrogol/electrolytes with magnesium hydroxide in the prevention of opioid-induced constipation in patients with cancer in the palliative (incurable) phase, who start opioids because …

This description comes directly from the study's public registry record.

Talk to the study team

Kay Kistemaker, MSc/MD  ·  +31 6 50087799  ·  k.kistemaker@amsterdamumc.nl

Lia van Zuylen, Prof. dr.  ·  +3120 4445571  ·  c.vanzuylen@amsterdamumc.nl

Always discuss trial participation with your own doctor first.

Locations (13)

FlevoziekenhuisAlmere Stad, Flevoland, NetherlandsRecruiting
Rijnstate ZiekenhuisArnhem, Gelderland, NetherlandsRecruiting
Radboud university Medical center NijmegenNijmegen, Gelderland, NetherlandsRecruiting
Jeroen Bosch Ziekenhuis's-Hertogenbosch, North Brabant, NetherlandsRecruiting
Amsterdam UMC, location VUmcAmsterdam, North Holland, NetherlandsRecruiting
Spaarne GasthuisHoofddorp, North Holland, NetherlandsRecruiting
Groene Hart HospitalGouda, South Holland, NetherlandsRecruiting
Leiden University Medical CenterLeiden, South Holland, NetherlandsRecruiting
Erasmus Medical CenterRotterdam, South Holland, NetherlandsRecruiting
Haaglanden Medical CentreThe Hague, South Holland, NetherlandsRecruiting
University Medical Center GroningenGroningen, NetherlandsRecruiting
Martini Hospital GroningenGroningen, NetherlandsRecruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05216328